Pretreatment SUV_max may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Paolo StratiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Mohamed Amin AhmedDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Loretta J. NastoupilDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Lei FengDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information

Fredrick B. HagemeisterDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Luis E. FayadDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Maria A. RodriguezDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Felipe SamaniegoDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Michael WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Jason R. WestinDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Hun J. LeeDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Swaminathan P. IyerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Simrit ParmarDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Sairah AhmedDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Ranjit NairDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Raphael E. SteinerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Mansoor NooraniDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Christopher R. FlowersDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

R. Eric DavisDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Nathan H. FowlerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Sattva S. NeelapuDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]
View further author information

Your download is now in progress and you may close this window